Abstract
BackgroundBlisibimod, a peptibody that inhibits B-cell activating factor (BAFF), was previously found [1] to be safe, efficacious and well-tolerated in patients with systemic lupus erythematosus (SLE) that participated in a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
